Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
PCOS (polycystic ovary syndrome), increasingly designated PMOS (polycystic metabolic ovary syndrome) to reflect its metabolic complexity, is far more prevalent than its classic presentation suggests, affecting roughly six percent of reproductive-age women and carrying systemic consequences well beyond fertility disruption. This chapter from the foundational NaProTECHNOLOGY textbook maps the hormonal architecture of the condition, its ovulatory defect patterns, its frequent co-occurrence with endometriosis, and the restorative surgical and cycle-tracking approaches developed at the Pope Paul VI Institute.
Andrology/Male FactorCriteria and ClassificationMedical TreatmentSurgical Correction
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Male infertility plays a clinically significant role in a large share of couples who struggle to conceive, yet standard laboratory criteria for semen analysis were designed primarily to predict success with assisted reproduction, not natural fertility. NaProTECHNOLOGY approaches male factor as a diagnosable condition with identifiable root causes, applying medical and surgical options aimed at restoring sperm function and combining that work with fertility-awareness charting to maximize the couple's chances of natural conception.
Progesterone safety in pregnancyCongenital anomaly risk and progesterone supportNatural progesterone versus synthetic progestins teratologyNaProTechnology pregnancy management
Thomas W. Hilgers, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Luteal phase and early pregnancy progesterone supplementation protocols are detailed, including indications derived from Creighton Model hormone profiles and dosing regimens for intramuscular and vaginal routes. Targeted progesterone support addresses a correctable physiological deficit identified through CrMS-guided monitoring, reducing early pregnancy loss in women with documented luteal insufficiency.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Preterm birth remains a leading cause of perinatal mortality, with rates in the United States rising significantly over the latter half of the twentieth century despite decades of awareness. NaProTechnology's integrated prevention approach, developed at the Pope Paul VI Institute, addresses this problem through systematic risk stratification, hormonal support, infection surveillance, and cervical monitoring across the full course of pregnancy.
NaProTECHNOLOGYIntroductory Session StructureBiological Valve MechanismChart Interpretation and Peak Day Identification
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
This 2004 textbook chapter by Thomas W. Hilgers outlines the structure and content of the formal introductory session used to enroll couples in the Creighton Model FertilityCare System (CrMS). It covers the biological foundation of fertility charting, the role of cervical mucus as a biomarker of the reproductive cycle, and the educational framework designed to train couples in systematic, real-time cycle observation.
NaProTECHNOLOGY nursing roleCreighton Model patient partnershipcycle-coordinated infertility schedulingFertilityCare Practitioner training
Thomas W. Hilgers, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Nursing within the NaProTECHNOLOGY practice encompasses preoperative preparation, intraoperative assistance, postoperative monitoring, hormone administration protocols, and patient education on cycle-based treatment timing. Nurses fluent in CrMS charting language and NaProTECHNOLOGY biomarker systems function as clinical integrators, ensuring that laboratory and treatment protocols are executed in alignment with the individualized menstrual cycle data driving each patient's care plan.
NaProTECHNOLOGY biomarkersCreighton Model cycle chartingovulation disorder classificationmucus cycle score and pregnancy outcomes
Thomas W. Hilgers, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
NaProTECHNOLOGY utilizes a defined panel of cycle-phase-specific biomarkers — including targeted progesterone, estradiol, LH, FSH, and prolactin drawn at CrMS-standardized cycle days — to characterize the hormonal profile underlying each patient's reproductive dysfunction. This biomarker summary consolidates reference ranges, collection timing rules, and clinical interpretation frameworks that govern diagnosis and treatment decisions across infertility, endometriosis, recurrent pregnancy loss, and cycle irregularity.
Thomas W. Hilgers, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Medical protocols in NaProTECHNOLOGY are cycle-phase-targeted regimens — covering ovulation induction, luteal phase hormonal support, hyperprolactinemia management, thyroid optimization, and pre-conceptual supplementation — derived from the biomarker-defined diagnosis rather than empirical stimulation. Consolidating these protocols in a single reference enables practitioners to apply evidence-based, individualized treatment sequences that address root hormonal pathology while supporting natural conception.
Cost-effectiveness analysis: NaProTechnology vs. conventional careInfertility treatment cost: IVF vs. NaProTechnology per successful pregnancyCreighton Model System cost vs. contraceptive methodsPrematurity prevention: national medical cost burden and projected savings
Thomas W. Hilgers, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
An economic analysis of NaProTECHNOLOGY compares the total treatment costs and cost-per-live-birth outcomes against assisted reproductive technologies, including IVF, drawing on outcome data from the Pope Paul VI Institute to demonstrate that NaPro's higher per-cycle success rates yield a favorable cost-effectiveness ratio despite comparable or lower upfront expenditures. Because NaProTECHNOLOGY identifies and corrects underlying pathology rather than bypassing it, its resource utilization model supports long-term gynecological health benefits that IVF cannot provide, making the economic case inseparable from the clinical one.
NaProTECHNOLOGY research program scope and quantitative foundationCreighton Model System mucus observation validationEvidence-based reproductive medicine and RCT limitationsResearch bias and funding asymmetry in reproductive health
Thomas W. Hilgers, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
A comprehensive, thematically organized compendium of citations documents the evidentiary foundations for every clinical protocol and outcome claim presented across the preceding 88 chapters, spanning foundational cervical mucus research through contemporary reproductive endocrinology and surgical outcomes literature. Consolidating this reference architecture in a dedicated chapter provides practitioners and researchers a structured pathway to primary literature, reinforcing that NaProTECHNOLOGY is grounded in a reproducible, peer-reviewed evidence base rather than institutional convention.
NaProTECHNOLOGY research agenda and future directionsCreighton Model computerized charting and biomarker technologyLuteal-phase hormone screening for cancer and bone density riskEvidence base critique of oral contraceptives and conventional reproductive medicine
Thomas W. Hilgers, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Hilgers articulates a programmatic vision for the global expansion of NaProTECHNOLOGY through the continued development of FertilityCare Centers International, advanced medical consultant training, and integration of longitudinal hormonal research into evolving clinical protocols. Establishing a roadmap for research priorities, practitioner education infrastructure, and broader medical acceptance positions NaProTECHNOLOGY as a scalable, restorative alternative to the prevailing ART-centered paradigm in reproductive medicine.
Fertility AwarenessAchieving- and Avoiding-Related BehaviorUse TaxonomyPregnancy Classification
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Chapter 13 of Hilgers' NaProTECHNOLOGY textbook establishes a clinical behavioral taxonomy unique to the Creighton Model FertilityCare System, distinguishing between achieving-related and avoiding-related use based on whether a couple's actions increase or decrease the probability of conception. The chapter argues that a "taking a chance" mindset is inherently contraceptive in psychology and must be replaced with intentional, education-grounded behavior that reflects a couple's genuine family planning goals.
Women's HealthEndometrial Cancer Risk and DetectionBreast Cancer Hormonal AssociationsOvarian Cancer Early Detection
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Chapter 34 of Hilgers (2004) examines how NaProTechnology cycle charting may identify women at elevated risk endometrial, breast, and ovarian. The chapter presents clinical case series and a small prospective study suggesting that observable cycle biomarkers, particularly patterns indicating suboptimal luteal-phase function, may precede diagnosis and could inform earlier evaluation, while calling explicitly for further research to validate these findings.
CREIGHTON MODEL FertilityCare System standardizationcervical mucus observation methodologyPicture Dictionary fertility chartingCrMS follow-up form and reproductive categories
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The structured protocols used to train and certify FertilityCare Practitioners (FCPs) in the uniform delivery of CrMS instruction are detailed, covering the sequence of follow-up sessions, the use of standardized teaching aids, and quality-control mechanisms that ensure inter-instructor consistency. Standardization is essential to the scientific validity of CrMS data, because chart comparability across practitioners and study populations depends on identical observation and recording conventions.
To determine the positive predictive value of the combined symptoms of severe dysmenorrhea with the sign of tenderness and/or nodularity of the cul-de-sac and/or uterosacral ligament(s) in diagnosing endometriosis clinically. In this prospective study, 116 patients with severe dysmenorrhea, after excluding urinary and gastrointestinal disease, underwent pelvic examination by the same investigator. Women having adnexal mass on pelvic examination were excluded Tenderness, and also nodularity, of the cul-de-sac, right and left uterosacral ligament were recorded separately. The laparoscopist did not know the findings of the pelvic examination. The diagnosis of endometriosis was made visually when lesions were typical and all other lesions were biopsied. The prevalence of endometriosis was 78.4%. Tenderness, nodularity, tenderness and nodularity, and also tenderness or nodularity of cul-de-sac and/or uterosacral ligament(s) were all statistically significantly associated with the presence of endometriosis (P = .048, .005, .004, and .004 respectively). The positive predictive values were 85.5%, 94.0%, 94.6% and 86.7%, respectively. The positive predictive value of severe dysmenorrhea with nodularity of the cul-de-sac and/or uterosacral ligament(s) was 94.0%.
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Endometriotic implants are catalogued across their full morphological spectrum—classic powder-burn lesions, red flame lesions, clear vesicles, white fibrotic plaques, and subtle vascular changes—with photographic documentation guiding surgical recognition. Familiarity with atypical implant appearances is essential because underrecognition of non-pigmented lesions leads to incomplete excision and persistent symptomatology.
early pregnancy loss ratesHertig-Rock study critiquehCG monitoring and implantationsubclinical pregnancy loss
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Early pregnancy loss encompasses biochemical pregnancy, embryonic demise, and missed abortion, each distinguished by specific hormonal profiles and ultrasound criteria within the NaProTECHNOLOGY surveillance model. CrMS-based cycle identification enables recognition of pregnancy at the earliest stages, allowing timely hormonal intervention when progesterone or estradiol deficits are detected.
Fertility AwarenessCreighton Model FertilityCare SystemCervical Mucus BiomarkersPeak Day Identification
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The content and sequence of the introductory and follow-up instructional sessions that constitute the formal CrMS education series are outlined, covering observation technique, recording conventions, and the practitioner-client interaction model. Consistent delivery of these core instructions establishes the behavioral competence required for both family planning use and the medical monitoring applications that NaProTECHNOLOGY depends upon.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Surgical NaProTECHNOLOGY is defined as a cooperative surgical discipline that corrects reproductive pathology identified through CrMS monitoring and targeted diagnostic workup, employing microsurgical and laser techniques that maximize tissue preservation and minimize adhesion formation. The philosophical and technical distinctions from conventional gynecologic surgery are established, emphasizing restorative intent and anatomical precision as core principles.
Pregnancy DatingEstimated Time of ConceptionCreighton Model vs UltrasoundGestational Age vs Fetal Age
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
NaProTECHNOLOGY uses the Peak Day of the Creighton Model chart — the last day of the most fertile-type cervical mucus — as the reference point for dating conception, providing a biologically grounded alternative to last menstrual period dating that remains accurate across irregular cycles. Precise cycle-based dating improves the clinical interpretation of early pregnancy hormone levels, ultrasound findings, and obstetric gestational age assignments, reducing unnecessary interventions triggered by apparent growth discordance.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Hilgers presents a refined classification of follicular and luteal phase deficiencies grounded in the integration of CrMS mucus pattern characteristics, cycle-phase-targeted estradiol and progesterone profiles, ultrasound folliculometry, and endometrial histology, introducing terminology that links specific chart signatures to defined endocrine subtypes and treatment protocols. Follicular deficiencies -- marked by short or poor-quality mucus phases and suboptimal estradiol -- and luteal deficiencies -- marked by a post-Peak phase under nine days, premenstrual spotting, or blunted serial progesterone curves -- are treated with tailored ovulation induction, cooperative progesterone replacement, and correction of contributing systemic disorders including thyroid dysfunction, hyperprolactinemia, and insulin resistance.
NaProTECHNOLOGY infertility outcomesper-woman pregnancy rate vs cycle-by-cycle IVF reportingIVF discontinuation rate and per-woman successmucus cycle pattern as fertility prognosis
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Cumulative pregnancy and live birth data from the Pope Paul VI Institute document NaProTECHNOLOGY outcomes across diagnostic categories including unexplained infertility, endometriosis, PCOD, and tubal disease, with multi-year follow-up that captures pregnancies occurring after continued treatment — a metric not captured in per-cycle ART statistics. These outcomes provide the evidence base for positioning NaProTECHNOLOGY as a first-line rather than last-resort reproductive medicine strategy.
Reproductive Endocrinology: HPO Axis: GnRH Pulse GeneratorReproductive Endocrinology: Neuroendocrine Modulation: Beta-Endorphin and Opioid PeptidesReproductive Endocrinology: Receptor Physiology: Steroid and LH Receptor DeficiencyInfertility: Cycle-Charting Correlates: Mucus Cycle and Ovulatory Defects
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Disruptions along the hypothalamic-pituitary-ovarian axis — including luteal phase deficiency, inadequate LH surges, and follicular maturation failure — are among the most common and underdiagnosed contributors to infertility and recurrent pregnancy loss. Targeted hormone supplementation guided by cycle-specific progesterone and estradiol assays, timed to CrMS biomarkers, restores functional ovulatory and luteal competence without suppressing the axis.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The sonographic ovulation classification is validated against targeted hormone profiles -- estradiol, LH, and serial post-Peak progesterone (P+3 through P+11) -- drawn at CrMS Peak-anchored time points rather than fixed calendar days. Hormone patterns corresponding to each sonographic category (e.g., absent LH surge in anovulation, progesterone rise without follicle rupture in LUF) confirm that ultrasound morphology reliably reflects the underlying endocrine disorder, establishing the biochemical legitimacy of the classification for clinical diagnosis.
Ectopic pregnancy diagnosis and managementCreighton Model System and early pregnancy detectionLaparoscopic subtotal salpingectomy techniqueCatholic medical ethics and principle of double effect
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Ectopic pregnancy demands prompt diagnosis and intervention to prevent life-threatening hemorrhage, and NaProTECHNOLOGY's CrMS-guided cycle monitoring enables earlier detection compared to symptom-driven presentations. Surgical management favors salpingotomy with tube preservation when feasible, aligned with the NaProTECHNOLOGY commitment to maintaining reproductive anatomy and future fertility potential.
NaProTECHNOLOGYFertilityCare Practitioner RoleMedical Consultant Referral LetterLong-Distance Consultation Model
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The FertilityCare Practitioner (FCP) is the trained educator and coach who teaches the Creighton Model FertilityCare System to clients, standardizes charting methodology, and serves as the primary data interface between the patient and the NaProTECHNOLOGY physician. Accurate, consistent chart data from FCPs directly determines the quality of biomarker interpretation, targeted intervention timing, and longitudinal outcome assessment throughout medical and surgical care.
NaProTECHNOLOGYParadigm ShiftProspective Cycle ChartingRoot-Cause vs Symptom Suppression
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
NaProTECHNOLOGY (Natural Procreative Technology) is defined as a women's health science that monitors and cooperates with the menstrual and fertility cycles to identify, evaluate, and treat gynecologic and reproductive disorders at their root cause. Unlike suppressive approaches such as hormonal contraception or ART, NaProTECHNOLOGY maintains procreative potential and treats underlying pathology while preserving the human ecology of reproduction.
Laser surgeryEndometriosis surgerySurgical adhesion preventionLaparoscopy vs laparotomy selection
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
CO2 laser vaporization technique for peritoneal and superficial ovarian endometriotic implants is described in detail, covering power density settings, spot size, vaporization depth control, and recognition of adequate treatment endpoints. Complete destruction of all visible implants, facilitated by the near-contact survey, is necessary to achieve durable symptom relief and improvement in fertility outcomes.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Premenstrual syndrome in NaProTECHNOLOGY is defined by a recurrent cluster of symptoms -- including irritability, breast tenderness, bloating, depression, and carbohydrate craving -- beginning at least four days before menses, and is associated with late-luteal deficiencies in progesterone, estrogen, and beta-endorphin identified through CrMS-anchored hormone profiling. Treatment with cycle-synchronized bioidentical progesterone, targeted HCG injections to stimulate endogenous corpus luteum function, and low-dose naltrexone to modulate opioid dynamics produces superior symptom resolution compared to SSRI therapy in Hilgers' comparative data, without suppressing ovulation.
Parnell T, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Reproductive outcomes in women aged 35 and older are analyzed using CrMS-monitored cycles, documenting that natural conception remains achievable when ovulatory function and hormonal sufficiency are maintained and underlying pathology is treated. NaProTECHNOLOGY's restorative approach offers an alternative to assisted reproduction for mature-age patients by identifying and correcting specific endocrine or anatomical barriers.
NaProTECHNOLOGY foundations and philosophyscience-ethics-faith integration in reproductive medicinerestorative versus suppressive reproductive medicineNaProTECHNOLOGY history and intellectual lineage
Mirkes R, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The philosophical and ethical foundation of NaProTECHNOLOGY is examined through the lens of a "new humanism" that affirms the dignity of women, couples, and the unborn by working within — rather than against — natural reproductive processes. Hilgers and contributing author Sr. Renee Mirkes situate NaProTECHNOLOGY within a broader critique of technologized reproductive medicine and articulate a coherent framework for procreative ethics applicable to clinical practice.
Fertility AwarenessCervical Mucus ObservationFecundity ResearchCreighton Model
Stanford JB, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The Mucus Cycle Score, derived from the standardized CrMS daily observations, quantifies cervical mucus quality and quantity across a cycle and correlates with measured estrogen levels and fecundity rates, providing a non-invasive index of reproductive potential. Declining mucus scores are clinically actionable, directing investigation into hypoestrogenism, cervical pathology, or medication effects that reduce cycle fecundity and can be corrected before ART is considered.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Proximal tubal occlusion at the uterotubal junction, whether from salpingitis isthmica nodosa, fibrosis, or prior sterilization, requires cornual resection and microsurgical tubal reimplantation to re-establish luminal continuity. NaProTECHNOLOGY treats this as a reconstructive procedure rather than a reason to defer to IVF, and outcomes data support intrauterine pregnancy rates comparable to assisted reproduction in appropriately selected patients.
NaProTECHNOLOGY professional infrastructure and credentialingCREIGHTON MODEL FertilityCare System organizational historyFertilityCare practitioner accreditation and certificationPope Paul VI Institute founding and research lineage
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The institutional architecture supporting the CrMS — including the FertilityCare Centers of America network, the American Academy of FertilityCare Professionals (AAFCP), training and certification pathways, and the research programs of the Pope Paul VI Institute — is described. This infrastructure is what distinguishes NaProTECHNOLOGY from informal fertility awareness methods, providing the professional standards, peer accountability, and ongoing research capacity required for clinical credibility.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Serial transvaginal ultrasound monitoring of follicular dynamics -- growth, rupture, corpus luteum formation, and free fluid -- forms the basis of a systematic classification of human ovulation disorders, including anovulation, luteinized unruptured follicle (LUF), follicular arrest, premature luteinization, and PCOS-type patterns. Anchoring sonographic findings to the CrMS Peak day allows precise correlation between ultrasound events and cervical mucus biomarkers, creating a reproducible diagnostic taxonomy that drives targeted medical and surgical treatment within the NaProTECHNOLOGY framework.
NaProTechnology outcomes after failed ARTUnexplained infertility reclassificationOvulation-timed hormone testingCreighton Model mucus charting as diagnostic tool
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Patients who have undergone multiple failed IVF cycles and are counseled to abandon fertility treatment represent a significant NaProTECHNOLOGY cohort in whom undiagnosed correctable pathology — including subtle endometriosis, luteal insufficiency, or immunological factors — is subsequently identified and treated. Published data demonstrate clinically meaningful pregnancy rates in this population following NaProTECHNOLOGY evaluation and treatment, demonstrating that ART failure does not predict failure of restorative approaches.
Creighton Model special-situation charting instructionsreturn of fertility after breastfeeding and postpartumdouble Peak and stress-related ovulation delaycervical mucus versus seminal and arousal fluid
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Adaptations of CrMS instruction for physiologically distinct reproductive states — including breastfeeding, post-hormonal contraceptive use, long or irregular cycles, and premenopause — are described with specific observational guidance for each context. These special protocols extend the clinical reach of the CrMS to all phases of a woman's reproductive life and ensure that charting remains interpretable even when cycle dynamics are atypical.
Postoperative CareSurgical ComplicationsReconstructive Pelvic SurgeryLaparoscopy vs Laparotomy
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Structured postoperative management following PEARS procedures addresses wound care, pain control, early ambulation, hormonal support, and surveillance for complications including bleeding, infection, urinary injury, and bowel complications. NaProTECHNOLOGY postoperative protocols integrate CrMS-guided hormonal monitoring to optimize the healing environment and time the resumption of targeted fertility treatment.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Preconceptional optimization using CrMS cycle data establishes hormonal baselines, identifies correctable pathologies, and guides targeted supplementation before conception is attempted. Systematic preconceptional evaluation reduces early pregnancy loss and improves obstetric outcomes by ensuring the endocrine environment supports implantation and early embryonic development.
Endometriosis/Diagnosis/Diagnostic LaparoscopyEndometriosis/Fertility Effects/Ovulatory and Luteal DysfunctionEndometriosis/Fertility Effects/Peritoneal Fluid ToxicityEndometriosis/Treatment/Surgical Excision vs Medical Suppression
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Endometriosis impairs fertility through direct mechanical distortion of pelvic anatomy, peritoneal inflammatory mediators, and hormonal micro-environment alterations that reduce implantation potential, making thorough surgical excision critical to restoring fertility rather than bypassing it. The PEARS classification system, used in NaProTECHNOLOGY surgical practice, enables standardized documentation of endometriotic disease extent and correlates operative findings with postoperative reproductive outcomes.
Menstrual CycleAbnormal Uterine BleedingCREIGHTON MODEL SystemLuteal Phase Dysfunction
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Unusual uterine bleeding -- including premenstrual spotting, tail-end brown bleeding, mid-cycle intermenstrual bleeding, and heavy menses -- is evaluated in NaProTECHNOLOGY through prospective CrMS charting combined with cycle-phase-targeted estradiol and serial post-Peak progesterone profiles, which typically reveal luteal phase deficiency, follicular estradiol insufficiency, or anovulation as the primary etiology. Treatment is etiology-directed cooperative progesterone replacement for luteal defects, follicular support or ovulation induction for follicular phase insufficiency, and fertility-sparing surgical correction for structural pathology such as endometriosis, polyps, or fibroids, without routine recourse to contraceptive suppression.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
NaProTECHNOLOGY foundational rationalecontraceptive technology and population health trendsassisted reproductive technology outcomes and multiple pregnancysexually transmitted disease burden United States
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Escalating rates of contraceptive use, abortion, divorce, child abuse, teenage pregnancy, and out-of-wedlock births over the preceding four decades are documented as interconnected indicators of systemic failure in women's and family healthcare. Hilgers argues these trends reflect a prevailing medical culture that suppresses or bypasses reproductive function rather than supporting it, establishing the clinical and moral imperative for a restorative alternative.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Deep infiltrating endometriosis involving the rectosigmoid, appendix, and small bowel is addressed through gynecologist-performed PEARS techniques that include superficial disc excision, appendectomy, and coordinated bowel resection when full-thickness involvement requires it. Recognition of intestinal endometriosis at laparoscopy and command of the relevant surgical steps allow the NaProTECHNOLOGY surgeon to treat the complete disease burden in a single operative setting.
NaProTECHNOLOGYCreighton Model FertilityCare SystemCervical eversion and ectropionChronic discharge charting and classification
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The Creighton Model's standardized daily vulvar observation system -- recording discharge color, consistency, quantity, and sensation -- allows chronic pathological discharges (persistent yellow or cloudy mucus, continuous post-Peak discharge, premenstrual brown bleeding, or refractory vulvovaginitis) to be distinguished from normal cyclical mucus patterns and tracked longitudinally as a diagnostic tool. NaProTECHNOLOGY uses chronic discharge patterns as biomarkers that prompt organism-specific cultures, targeted hormonal evaluation, ultrasound, and etiology-directed treatment -- including antimicrobials, cooperative hormone replacement, or fertility-sparing surgery -- rather than empirical cycle suppression.
Endometriosis surgical treatment and recurrenceExcision vs ablation: site-specific durabilitySecond-look laparoscopy as recurrence assessment standardNaProTECHNOLOGY endometriosis outcomes
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Endometriosis recurrence after surgical excision remains a clinical reality driven by residual ectopic implants, persistent hormonal milieu favoring re-seeding, and incomplete initial resection. NaProTECHNOLOGY addresses recurrence risk through postoperative hormone normalization guided by CrMS biomarkers, with repeat PEARS reserved for symptomatic or fertility-impairing recurrence confirmed by clinical and laparoscopic assessment.
NaProTECHNOLOGY terminology: isomolecular hormones vs heteromolecular artimonesCardiovascular hormone therapy: PEPI, HERS, ERA trial reanalysisProgesterone receptor isoforms PR-A and PR-B: opposing transcriptional rolesBioidentical progesterone: breast tissue, brain, and bone effects
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Hilgers distinguishes isomolecular hormones -- molecules structurally identical to endogenous estradiol and progesterone -- from heteromolecular artimones, his term for synthetic analogues such as medroxyprogesterone acetate, norethindrone, and ethinyl estradiol, which differ in receptor binding, metabolic pathways, and systemic effects. NaProTECHNOLOGY restricts hormone therapy to isomolecular compounds administered in cycle-synchronized, physiologic doses because artimones suppress the hypothalamic-pituitary-ovarian axis, mask underlying pathology, and produce non-physiologic metabolite profiles incompatible with a restorative reproductive medicine approach.
Creighton Model effectiveness measurementbehavioral vs intentional pregnancy classificationlife-table and Pearl rate methodologyNFP study design and denominator construction
Stanford JB, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Methodologically rigorous effectiveness data for the CrMS are presented, including method-effectiveness and use-effectiveness rates for pregnancy avoidance drawn from prospective cohort studies, demonstrating rates comparable to or exceeding hormonal contraception. Standardized outcome measurement is necessary to establish the CrMS's scientific credibility and to provide practitioners and patients with accurate, evidence-based counseling on system performance.